S&P 500   5,123.41
DOW   37,983.24
QQQ   438.27
5 Trends You Need to Know This Quarter
MarketBeat Week in Review – 4/8 - 4/12
Diplomat tapped as Latvia's new foreign minister as incumbent quits following flights scandal
Germany's Scholz arrives in China on a visit marked by trade tensions and Ukraine conflict
It's almost April 15. Here's how to reduce stress and get your taxes done
India's Modi vows to boost social spending, make country into a manufacturing hub ahead of election
Israel hails 'success' in blocking Iran's unprecedented attack. Biden now seeks diplomatic response
S&P 500   5,123.41
DOW   37,983.24
QQQ   438.27
5 Trends You Need to Know This Quarter
MarketBeat Week in Review – 4/8 - 4/12
Diplomat tapped as Latvia's new foreign minister as incumbent quits following flights scandal
Germany's Scholz arrives in China on a visit marked by trade tensions and Ukraine conflict
It's almost April 15. Here's how to reduce stress and get your taxes done
India's Modi vows to boost social spending, make country into a manufacturing hub ahead of election
Israel hails 'success' in blocking Iran's unprecedented attack. Biden now seeks diplomatic response
S&P 500   5,123.41
DOW   37,983.24
QQQ   438.27
5 Trends You Need to Know This Quarter
MarketBeat Week in Review – 4/8 - 4/12
Diplomat tapped as Latvia's new foreign minister as incumbent quits following flights scandal
Germany's Scholz arrives in China on a visit marked by trade tensions and Ukraine conflict
It's almost April 15. Here's how to reduce stress and get your taxes done
India's Modi vows to boost social spending, make country into a manufacturing hub ahead of election
Israel hails 'success' in blocking Iran's unprecedented attack. Biden now seeks diplomatic response
S&P 500   5,123.41
DOW   37,983.24
QQQ   438.27
5 Trends You Need to Know This Quarter
MarketBeat Week in Review – 4/8 - 4/12
Diplomat tapped as Latvia's new foreign minister as incumbent quits following flights scandal
Germany's Scholz arrives in China on a visit marked by trade tensions and Ukraine conflict
It's almost April 15. Here's how to reduce stress and get your taxes done
India's Modi vows to boost social spending, make country into a manufacturing hub ahead of election
Israel hails 'success' in blocking Iran's unprecedented attack. Biden now seeks diplomatic response
NASDAQ:MEDP

Medpace (MEDP) Stock Price, News & Analysis

$395.00
-7.30 (-1.81%)
(As of 04/12/2024 ET)
Today's Range
$392.71
$399.99
50-Day Range
$295.29
$413.31
52-Week Range
$185.43
$419.42
Volume
133,733 shs
Average Volume
191,936 shs
Market Capitalization
$12.24 billion
P/E Ratio
44.48
Dividend Yield
N/A
Price Target
$382.00

Medpace MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.75 Rating Score
Upside/​Downside
3.3% Downside
$382.00 Price Target
Short Interest
Healthy
3.82% of Float Sold Short
Dividend Strength
N/A
Sustainability
-0.62
Upright™ Environmental Score
News Sentiment
1.42mentions of Medpace in the last 14 days
Based on 7 Articles This Week
Insider Trading
Selling Shares
$76.65 M Sold Last Quarter
Proj. Earnings Growth
20.89%
From $10.53 to $12.73 Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

4.55 out of 5 stars

Medical Sector

96th out of 926 stocks

Commercial Physical Research Industry

4th out of 10 stocks

MEDP stock logo

About Medpace Stock (NASDAQ:MEDP)

Medpace Holdings, Inc. provides clinical research-based drug and medical device development services in North America, Europe, and Asia. The company offers a suite of services supporting the clinical development process from Phase I to Phase IV in various therapeutic areas. It provides clinical development services to the pharmaceutical, biotechnology, and medical device industries; and development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support services. In addition, the company offers bio-analytical laboratory services, clinical human pharmacology, imaging services, and electrocardiography reading support for clinical trials. Medpace Holdings, Inc. was founded in 1992 and is based in Cincinnati, Ohio.

MEDP Stock Price History

MEDP Stock News Headlines

Red Alert: Your Money's Disappearance Act - Banks' Greed Unleashed!
Get your free information kit NOW, before it’s too late. Inside you’ll get the 3 secret strategies you can put in place starting today, so “they” don’t get your money tomorrow.
Red Alert: Your Money's Disappearance Act - Banks' Greed Unleashed!
Get your free information kit NOW, before it’s too late. Inside you’ll get the 3 secret strategies you can put in place starting today, so “they” don’t get your money tomorrow.
Should You Invest in Medpace (MEDP)?
Insiders Are Selling These 5 Stocks in 2024
MEDP Apr 2024 580.000 call
Assessing Medpace Hldgs: Insights From 4 Financial Analysts
MEDP Jun 2024 380.000 call
Medpace Holdings
See More Headlines
Receive MEDP Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Medpace and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
2/12/2024
Today
4/13/2024
Next Earnings (Confirmed)
4/22/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Commercial physical research
Sub-Industry
N/A
Current Symbol
NASDAQ:MEDP
Employees
5,900
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$382.00
High Stock Price Target
$452.00
Low Stock Price Target
$273.00
Potential Upside/Downside
-3.3%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.75
Research Coverage
4 Analysts

Profitability

Net Income
$282.81 million
Pretax Margin
17.80%

Debt

Sales & Book Value

Annual Sales
$1.89 billion
Cash Flow
$9.89 per share
Book Value
$18.22 per share

Miscellaneous

Free Float
23,020,000
Market Cap
$12.24 billion
Optionable
Optionable
Beta
1.38
These 7 Stocks Will Be Magnificent in 2024 Cover

With average gains of 150% since the start of 2023, now is the time to give these stocks a look and pump up your 2024 portfolio.

Get This Free Report

MEDP Stock Analysis - Frequently Asked Questions

Should I buy or sell Medpace stock right now?

4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Medpace in the last twelve months. There are currently 1 hold rating and 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" MEDP shares.
View MEDP analyst ratings
or view top-rated stocks.

What is Medpace's stock price target for 2024?

4 brokers have issued 1-year price objectives for Medpace's stock. Their MEDP share price targets range from $273.00 to $452.00. On average, they predict the company's share price to reach $382.00 in the next twelve months. This suggests that the stock has a possible downside of 3.3%.
View analysts price targets for MEDP
or view top-rated stocks among Wall Street analysts.

How have MEDP shares performed in 2024?

Medpace's stock was trading at $306.53 on January 1st, 2024. Since then, MEDP stock has increased by 28.9% and is now trading at $395.00.
View the best growth stocks for 2024 here
.

When is Medpace's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, April 22nd 2024.
View our MEDP earnings forecast
.

How can I listen to Medpace's earnings call?

Medpace will be holding an earnings conference call on Tuesday, April 23rd at 9:00 AM Eastern. Interested parties can register for or listen to the call using this link.

How were Medpace's earnings last quarter?

Medpace Holdings, Inc. (NASDAQ:MEDP) issued its quarterly earnings data on Monday, February, 12th. The company reported $2.46 earnings per share for the quarter, beating the consensus estimate of $2.22 by $0.24. The business had revenue of $498.40 million for the quarter, compared to the consensus estimate of $498.72 million. Medpace had a trailing twelve-month return on equity of 63.98% and a net margin of 15.00%. The business's revenue for the quarter was up 26.5% compared to the same quarter last year. During the same quarter last year, the company earned $2.12 earnings per share.

What guidance has Medpace issued on next quarter's earnings?

Medpace issued an update on its FY 2024 earnings guidance on Tuesday, February, 13th. The company provided EPS guidance of 10.180-10.870 for the period, compared to the consensus EPS estimate of 9.960. The company issued revenue guidance of $2.2 billion-$2.2 billion, compared to the consensus revenue estimate of $2.2 billion.

What is August Troendle's approval rating as Medpace's CEO?

268 employees have rated Medpace Chief Executive Officer August Troendle on Glassdoor.com. August Troendle has an approval rating of 34% among the company's employees. This puts August Troendle in the bottom 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Medpace own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Medpace investors own include NVIDIA (NVDA), Exact Sciences (EXAS), Block (SQ), Baidu (BIDU), JD.com (JD), Advanced Micro Devices (AMD), Bilibili (BILI), Alibaba Group (BABA), Cisco Systems (CSCO) and Intuitive Surgical (ISRG).

When did Medpace IPO?

Medpace (MEDP) raised $150 million in an initial public offering on Thursday, August 11th 2016. The company issued 7,000,000 shares at $20.00-$23.00 per share. Jefferies, Credit Suisse, UBS Investment Bank and Wells Fargo Securities acted as the underwriters for the IPO and Baird and William Blair were co-managers.

Who are Medpace's major shareholders?

Medpace's stock is owned by many different institutional and retail investors. Top institutional investors include Los Angeles Capital Management LLC (0.85%), Congress Asset Management Co. MA (0.50%), Westwind Capital (0.14%), Annex Advisory Services LLC (0.13%), Rheos Capital Works Inc. (0.08%) and Bridge City Capital LLC (0.06%). Insiders that own company stock include Ashley M Keating, August J Troendle, August J Troendle, Jesse J Geiger, Kevin M Brady, Medpace Investors, Llc, Peter J O'malley, Robert O Kraft, Stephen P Ewald, Susan E Burwig, Tom C King and Wedbush Securities Inc.
View institutional ownership trends
.

How do I buy shares of Medpace?

Shares of MEDP stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:MEDP) was last updated on 4/14/2024 by MarketBeat.com Staff

From Our Partners